NICE Guideline: Depression in children and young people

The NICE guideline for depression in children and young people has been updated, with a number of changes to the recommendations for safe and effective antidepressant use.

Depression in children and young people: Identification and management in primary, community and secondary care
NICE guidelines [CG28]
March 2015

Find out more here.

Advice from NICE on Medicines Optimisation of Key Therapies

NICE have released a number of evidence-based Key Therapeutic Topics to support medicines optimisation. Access them below:

• Antibiotic prescribing – especially broad spectrum antibiotics (KTT9)
• First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8) 
• Low-dose antipsychotics in people with dementia (KTT7)
• Hypnotics (KTT6)
• High-dose inhaled corticosteroids in asthma (KTT5)
• Omega-3 fatty acid supplements (KTT4)
• Lipid-modifying drugs (KTT3)
• Renin-angiotensin system drugs (KTT2)
• Wound care products (KTT14)
• Non-steroidal anti-inflammatory drugs (KTT13)
• Type 2 diabetes mellitus (KTT12)
• Minocycline (KTT11)
• Three-day courses of antibiotics for uncomplicated urinary tract infection
• Laxatives (KTT1)

Focus on: antidepressant prescribing

"These analyses suggest that there is a complex interaction of factors driving the ever-increasing prescribing of antidepressants – acting at individual level, practice level and across broader society."

Focus on: antidepressant prescribing: trends in the prescribing of antidepressants in primary care (Quality Watch)

R Spence, A Roberts, C Ariti, M Bardsley

The Health Foundation, Nuffield Trust

May 2014

Read more here.